TNDM Tandem Diabetes Care | $35.24
-0.9% | 4/25/2024 | Upgraded by | Leerink Partnrs | Analyst M. Kratky | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
CVAC CureVac | $2.33
+0.9% | 4/25/2024 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
RNAC Cartesian Therapeutics | $21.03
+0.6% | 4/23/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $21.00
+11.3% | 4/16/2024 | Reiterated by | Leerink Partnrs | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partnrs rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $8.52
| 4/15/2024 | Reiterated by | Leerink Partnrs | Analyst R. Li | Outperform | | Low | View details for Leerink Partnrs rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $15.72
+1.7% | 4/15/2024 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partnrs rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
|
ALPN Alpine Immune Sciences | $64.56
-0.1% | 4/11/2024 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Alpine Immune Sciences (NASDAQ:ALPN) on 4/11/2024 |
SWAV Shockwave Medical | $330.00
+0.3% | 4/5/2024 | Downgraded by | Leerink Partnrs | Analyst M. Kratky | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Shockwave Medical (NASDAQ:SWAV) on 4/5/2024 |
ARDX Ardelyx | $6.42
+1.7% | 4/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $6.44
+1.7% | 4/3/2024 | Reiterated by | Leerink Partnrs | Analyst J. Park | Outperform | | Low | View details for Leerink Partnrs rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $66.86
+1.2% | 4/1/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $4.06
+3.6% | 3/25/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
FUSN Fusion Pharmaceuticals | $21.42
+0.1% | 3/19/2024 | Downgraded by | Leerink Partnrs | Analyst F. Khurshid | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 3/19/2024 |
RGLS Regulus Therapeutics | $2.42
+6.6% | 3/18/2024 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Outperform | | Low | View details for Leerink Partnrs rating of Regulus Therapeutics (NASDAQ:RGLS) on 3/18/2024 |
SPRB Spruce Biosciences | $0.70
| 3/14/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Spruce Biosciences (NASDAQ:SPRB) on 3/14/2024 |
AMLX Amylyx Pharmaceuticals | $1.76
-1.1% | 3/11/2024 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $16.19
+0.8% | 3/6/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $8.35
+3.2% | 3/5/2024 | Upgraded by | Leerink Partnrs | Analyst R. Ruiz | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $15.47
-2.9% | 3/4/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
IDYA IDEAYA Biosciences | $39.94
+3.4% | 2/23/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 2/23/2024 |
DOCS Doximity | $23.82
+1.0% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $16.57
+1.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Certara (NASDAQ:CERT) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $30.57
+0.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
RLAY Relay Therapeutics | $6.37
+3.4% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 2/22/2024 |
PGNY Progyny | $32.04
-1.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
NVST Envista | $20.39
+1.8% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Underperform | | Low | View details for Leerink Partnrs rating of Envista (NYSE:NVST) on 2/26/2024 |
NUVL Nuvalent | $66.86
+1.2% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 2/22/2024 |
LH Laboratory Co. of America | $198.40
+0.0% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Laboratory Co. of America (NYSE:LH) on 2/26/2024 |
DGX Quest Diagnostics | $134.26
-0.9% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
COGT Cogent Biosciences | $6.02
+0.2% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Cogent Biosciences (NASDAQ:COGT) on 2/22/2024 |
ARVN Arvinas | $32.37
+2.4% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Arvinas (NASDAQ:ARVN) on 2/22/2024 |
ALGN Align Technology | $309.02
-0.5% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
ACCD Accolade | $7.89
-14.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Accolade (NASDAQ:ACCD) on 2/26/2024 |
WBA Walgreens Boots Alliance | $17.70
+0.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
TDOC Teladoc Health | $13.01
-2.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
RCM R1 RCM | $11.90
+0.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of R1 RCM (NASDAQ:RCM) on 2/26/2024 |
PINC Premier | $20.96
+0.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Market Perform | | Low | View details for Leerink Partnrs rating of Premier (NASDAQ:PINC) on 2/26/2024 |
PDCO Patterson Companies | $25.77
-0.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Patterson Companies (NASDAQ:PDCO) on 2/26/2024 |
OMI Owens & Minor | $25.10
+4.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $543.37
+0.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of McKesson (NYSE:MCK) on 2/26/2024 |
Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad) 4x Better than Bitcoin
Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> |
IQV IQVIA | $234.88
+0.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Outperform | | Low | View details for Leerink Partnrs rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HSIC Henry Schein | $73.13
+0.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
HIMS Hims & Hers Health | $12.50
+1.9% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $7.19
+1.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Outperform | | Low | View details for Leerink Partnrs rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
CVS CVS Health | $67.18
-0.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 2/26/2024 |
COR Cencora | $240.88
+0.5% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $103.20
-0.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
APLT Applied Therapeutics | $4.28
+1.2% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Outperform | | Low | View details for Leerink Partnrs rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT RAPT Therapeutics | $8.10
+3.8% | 2/21/2024 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of RAPT Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
ENGN enGene | $15.50
+5.3% | 2/20/2024 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
BTSG BrightSpring Health Services | $10.58
+1.6% | 2/20/2024 | Reiterated by | Leerink Partnrs | Analyst W. Mayo | Outperform | | Low | View details for Leerink Partnrs rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
SYBX Synlogic | $1.87
+0.5% | 2/9/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $269.98
+0.2% | 2/7/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $233.85
-0.9% | 2/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
TSVT 2seventy bio | $4.26
-0.9% | 1/31/2024 | Upgraded by | Leerink Partnrs | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 |
NPCE NeuroPace | $13.39
+3.1% | 1/30/2024 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $13.73
-3.7% | 1/29/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $4.30
| 1/23/2024 | Reiterated by | Leerink Partnrs | Analyst J. La. Rosa | Outperform | | Low | View details for Leerink Partnrs rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AGL agilon health | $5.00
-2.5% | 1/8/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of agilon health (NYSE:AGL) on 1/8/2024 |
KRTX Karuna Therapeutics | $329.83
| 12/22/2023 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Karuna Therapeutics (NASDAQ:KRTX) on 12/22/2023 |
ALVR AlloVir | $0.80
| 12/22/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $4.66
-1.7% | 12/19/2023 | Upgraded by | Leerink Partnrs | Analyst J. Schwartz | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
NBTX Nanobiotix | $5.74
-2.9% | 12/8/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TRML Tourmaline Bio | $15.68
-2.0% | 12/7/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Tourmaline Bio (NASDAQ:TRML) on 12/7/2023 |
MOR MorphoSys | $18.04
-0.5% | 12/6/2023 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform | | Low | View details for Leerink Partnrs rating of MorphoSys (NASDAQ:MOR) on 12/6/2023 |
TNYA Tenaya Therapeutics | $4.31
+2.1% | 11/30/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
LXEO Lexeo Therapeutics | $12.50
+2.8% | 11/28/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $15.78
+0.3% | 11/14/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
ACRS Aclaris Therapeutics | $1.20
+0.8% | 11/13/2023 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/13/2023 |
ZNTL Zentalis Pharmaceuticals | $11.06
+0.7% | 11/7/2023 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $4.26
-0.9% | 10/30/2023 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
BEAM Beam Therapeutics | $21.38
-1.0% | 10/20/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
OLK Olink Holding AB (publ) | $22.84
-1.0% | 10/17/2023 | Downgraded by | Leerink Partnrs | Analyst P. Souda | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Olink Holding AB (publ) (NASDAQ:OLK) on 10/17/2023 |
FDMT 4D Molecular Therapeutics | $23.25
-1.2% | 10/18/2023 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
PLRX Pliant Therapeutics | $11.81
-0.6% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 10/16/2023 |
MORF Morphic | $28.07
+0.3% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Morphic (NASDAQ:MORF) on 10/16/2023 |
KYMR Kymera Therapeutics | $33.37
+0.1% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Market Perform | | Low | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/16/2023 |
VCEL Vericel | $46.05
+1.3% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
TNDM Tandem Diabetes Care | $35.24
-0.9% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
SWAV Shockwave Medical | $330.00
+0.3% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Shockwave Medical (NASDAQ:SWAV) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $51.83
-0.9% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
PODD Insulet | $166.19
+1.2% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
INSP Inspire Medical Systems | $237.45
+2.8% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
EW Edwards Lifesciences | $86.43
-1.8% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
DXCM DexCom | $124.34
-9.9% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
AXNX Axonics | $66.69
+0.2% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Axonics (NASDAQ:AXNX) on 10/16/2023 |
GILD Gilead Sciences | $65.42
+0.2% | 10/11/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform | | Low | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/11/2023 |
AMGN Amgen | $269.98
+0.2% | 10/11/2023 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
ACLX Arcellx | $51.92
+1.1% | 10/12/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Outperform | | Low | View details for Leerink Partnrs rating of Arcellx (NASDAQ:ACLX) on 10/12/2023 |
SPRY ARS Pharmaceuticals | $8.35
+3.2% | 9/21/2023 | Downgraded by | Leerink Partnrs | Analyst R. Ruiz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
Protect Yourself While There’s Still Time … (Ad) The next step of the Fed's control is here.
Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week.
Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. |
TSBX Turnstone Biologics | $2.76
-4.8% | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform | | Low | View details for Leerink Partnrs rating of Turnstone Biologics (NASDAQ:TSBX) on 8/15/2023 |
GLTO Galecto | $0.70
+4.5% | 8/15/2023 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Galecto (NASDAQ:GLTO) on 8/15/2023 |
DSGN Design Therapeutics | $3.78
+0.5% | 8/15/2023 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $65.34
+0.8% | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
RLAY Relay Therapeutics | $6.37
+3.4% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform | | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
NUVL Nuvalent | $66.86
+1.2% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $39.94
+3.4% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
EXEL Exelixis | $23.70
+0.7% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform | | Low | View details for Leerink Partnrs rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
QTRX Quanterix | $15.56
-0.2% | 8/8/2023 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
NVCR NovoCure | $12.64
+3.3% | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
WVE Wave Life Sciences | $4.66
-1.7% | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Market Perform | | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 8/4/2023 |
BLTE Belite Bio | $39.75
+4.6% | 7/26/2023 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partnrs rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
